[5]Tolaney SM,Tarantino P,Graham N,et al.Adjuvant paclitaxel and trastuzumab for node-negative,HER2-positive breast cancer:final 10-year analysis of the open-label,single-arm,phase 2 APT trial.Lancet Oncol.2023 Mar;24(3):273-285. [6]Tolaney SM,Barry WT,Dang CT,et al.Adjuvant paclitaxe...
参考文献: [1] Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021 Aug;22(8):1151-1161. [2] Li Y, Abudurehei...
Her2 positive and triple negative breast cancer patients with clinically negative nodes at diagnosis and breast pathologic complete response may spare axillary surgery after neoadjuvant treatmentdoi:10.1016/S0959-8049(18)30288-0Siso, C.Esgueva, A....
If yourbreast cancerhas a significant number of receptors for either estrogen or progesterone, it’s considered hormone-receptor positive. Tumors that are ER/PR-positive are much more likely to respond to hormone therapy than tumors that are ER/PR-negative. ...
Chaudhary LN, Jorns JM, Sun Y, et al. Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy. Breast Cancer Res Treat. 2023;201(...
[10]Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
《Clinical Cancer Research》于2022年8月31日在线发表了《Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-positive, HER2-negative Primary Breast Cancer》研究评价了EndoPredict 在绝经前女性中的评估可靠性 管腔雌激素受体阳性 (ER+)、人表皮生长因子2阴性 (HER2-)乳腺癌(BC)是 BC 中最常诊...
[21]JoergerM, ThürlimannB, HuoberJ. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment? [J]. Ann Oncol, 2011, 22(1): 17-23. DOI: 10.1093/annonc/mdq304. [24]JonesSE, ColleaR, PaulD, et al. Adjuvant docetaxel and cyclophosphamide plus trast...
[19]Burstein HJ, DeMichele A, Fallowfield L, et al. Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update. J Clin Oncol. 2024 Mar 13:JCO2400248. ...